MRNA technology takes on the stomach flu: moderna launches norovirus vaccine trial
NCT ID NCT05992935
First seen Mar 08, 2026 · Last updated Jun 23, 2026 · Updated 15 times
Summary
This study tests two experimental mRNA vaccines, mRNA-1403 and mRNA-1405, designed to prevent norovirus, a common cause of severe vomiting and diarrhea. Around 1,400 healthy adults aged 18 to 80 will receive either a vaccine or a placebo. The main goals are to check safety and measure the immune response.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NOROVIRUS ACUTE GASTROENTERITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
ARK Clinical Research, LLC
Long Beach, California, 90815, United States
-
Accel Research Sites Network
Decatur, Georgia, 30030, United States
-
Emeritus Research Camberwell
Camberwell, Australia
-
Epic Medical Research, LLC
Red Oak, Texas, 75154, United States
-
JBR Clinical Research
Salt Lake City, Utah, 84107, United States
-
Johnson County Clin-Trials (JCCT)
Lenexa, Kansas, 66219, United States
-
Nucleus Network
Melbourne, Australia
-
Optimal Research
Peoria, Illinois, 61614, United States
-
Research Centers of America
Hollywood, Florida, 33024, United States
-
Rochester Clinical Research, Inc
Rochester, New York, 14609, United States
-
Tekton Research, Inc - Longmont Center
Longmont, Colorado, 80501, United States
-
Velocity Clinical Research
Sioux City, Iowa, 51106, United States
-
Velocity Clinical Research
Rockville, Maryland, 20854, United States
-
Velocity Clinical Research
Norfolk, Nebraska, 68701, United States
-
Velocity Clinical Research
Omaha, Nebraska, 68134, United States
-
Velocity Clinical Research - Boise
Meridian, Idaho, 83642, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
mRNA-1403 and mRNA-1405 vaccines
What this could lead to
If successful, this could lead to the first approved vaccine to prevent norovirus, a highly contagious stomach bug causing severe vomiting and diarrhea.
What could go wrong
This is an early phase 1/2 trial focused on safety and immune response, not yet proving the vaccine prevents illness. Side effects like injection site pain or fever are possible.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.